Over the years, I’ve been involved with many clinical trials that could be considered to be ‘in rescue’ as a result of not recruiting a sufficient number of patients in a timely manner.

Indeed, for some organizations, this seems to be the default approach, seemingly being factored into the strategy from the outset.

Which seems to be a particularly inefficient way of planning a recruitment campaign, as things would likely work out better if the plan was to ensure a good number of patients being recruited from the outset, rather than anticipating a slow start followed by a scramble to get the numbers up later down the line.

It’s an odd mindset that believes that the kind of activities required for enhanced recruitment can only be implemented once a trial needs to be rescued.

With surely a better way of going about things being to adopt those strategies at launch in order to achieve targets sooner.

You may also like

Biotech C-suites Should keep Patient Recruitment in Mind from the Outset
In biotech, a strong C-suite isn’t just about job titles - it’s about covering every part of the journey from discovery to delivery. Including being prepared to tackle one of the biggest ...
Key C-suite Roles for Biotech Success - The Chief Patient Recruitment Officer (CPRO)
While biotech companies have built C-suites with scientific, medical, financial, operational, and business expertise, a critical function has remained conspicuously absent - addressing one ...
Key C-suite Roles for Biotech Success - The Chief Business Officer (CBO)
The Chief Business Officer leads external strategy - licensing deals, identifying pharma partnerships, and developing long-term growth planning and market positioning strategies that ...